- Markets
Find out what influences market movements by browsing through our tailor made product pages.
- Trading Platforms
Maximise your investment opportunities
Trading Platforms
In order to ensure our customers have the best trading experience. We are proud to introduce our suite of trading platforms.
- Accounts
All accounts can be opened using one application form.
OPEN A LIVE ACCOUNT
The application process is simple and straightforward. You can complete the online application form and be trading in minutes.
- Academy
Here you will find all the details regarding One Financial Markets educational offering
TRADING ACADEMY
Working through each of our six online modules, detailed below, you can develop your trading confidence
- Newsroom
The latest news in the Financial Markets from across the globe.
LATEST NEWS
Make sure you don't miss out on what's going on in the world around you, keep up to date with our market commentary and daily market update videos.
- Contact Us
4 big analyst cuts: Oracle slashed at JPMorgan on flimsy guidance
Investing.com -- Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Oracle, Acelyrin, Ecopetrol, and Ultrapar.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
Oracle downgraded again
Oracle (NYSE:ORCL) was cut to Neutral from Overweight at JPMorgan on Wednesday after the company issued soft Q2 guidance that saw shares drop more than 13% in Tuesday's session.
The company said intense competition within the cloud-computing sector and a reduction in digital spending were weighing on its top-line growth.
JPMorgan also trimmed the software giant's price target to $100 from $112. The analysts said that, while Oracle still has strengths such as strong growth in its cloud segment, AI-related business wins, margin expansion, and healthy recurring revenue growth, its valuation has reached over 25x EV/uFCF, making it difficult to justify a higher price target.
The analysts also cited a recent Generative AI CIO Survey in June that raised questions about Oracle's positioning.
The downgrade follows Tuesday's cut at Monness, Crespi, Hardt, which also downgraded Oracle to Neutral.
Acelyrin slashed at Morgan Stanley following disappointing Izokibep trial results
Morgan Stanley downgraded Acelyrin (NASDAQ:SLRN) to Equalweight from Overweight and cut its price target to $19.00 from $39.00, as reported in real time on InvestingPro.
Shares plunged more than 54% Tuesday after the company’s Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa (HS) didn’t hit the primary endpoint.
The analysts say the downgrade comes on increased uncertainty regarding HS and the challenging short-term prospects for the company. However, Morgan Stanley plans to re-evaluate its views later this year, when they say the setup for the company may be significantly improved.
Two more downgrades
Citi downgraded Ecopetrol (NYSE:EC)to Neutral from Buy with a price target of $12.50.
Goldman Sachs downgraded Ultrapar (NYSE:UGP) to Neutral from Buy with a price target of $4.00.
Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.
Start your free 7-day trial now.
Begin trading today! Create an account by completing our form
Privacy Notice
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.